Results of the votes of the combined shareholders' general meeting of december 11, 2024

Daix (france), new york city (new york, united states), december 11, 2024 – inventiva (euronext paris and nasdaq: iva) (the “company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“mash”), also known as non-alcoholic steatohepatitis (“nash”), and other diseases with significant unmet medical needs, today announced the results of the votes of its combined shareholders' meeting.
GM Ratings Summary
GM Quant Ranking